Skip to content
FY'25FY'24FY'23FY'22
$46.02M-89.4%$434.43M+624%$60M+126%$26.58M-2.8%
$159.29M+15.3%$138.13M+15.0%$120.16M-4.8%$126.22M+0.2%
$44.85M+3.2%$43.46M+29.8%$33.49M+5.5%$31.74M+16.7%
$204.14M+12.4%$181.59M+18.2%$153.65M-2.7%$157.95M+3.1%
$204.14M+12.4%$181.59M+18.2%$153.65M-2.7%$157.95M+3.1%
-$158.13M-163%$252.84M-$131.37M-4.4%
-343.6%-402pp58.2%-494.2%-34.2pp
$28.79M+9.4%$26.32M+76.6%$14.9M+267%$4.06M+816%
$250K
-$129.31M-146%$279.41M-$127.39M-1.5%
$838K-80.1%$4.22M$0
-$130.15M-147%$275.19M-$127.39M-1.5%
-282.8%-346pp63.3%-479.3%-20.3pp
-$2.06-149%$4.23-$2.61+3.3%
-$2.06-146%$4.50-$2.61+3.3%
253.8M+0.8%251.7M+12.7%223.3M+14.0%196M+6.8%
253.8M+3.4%245.5M+9.9%223.3M+14.0%196M+6.8%
$250K
-$158.13M-163%$252.84M-$131.37M-4.4%
-$156.85M-162%$253.67M-$130.34M-4.2%
-$156.85M-162%$253.67M-$130.34M-4.2%
-340.9%-399pp58.4%-490.3%-33.3pp
-$158.13M-163%$252.84M-$131.37M-4.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Protagonist Therapeutics's revenue?
Protagonist Therapeutics (PTGX) generated $74.1M in revenue over the trailing twelve months, down 64.4% year over year.
Is Protagonist Therapeutics profitable?
Protagonist Therapeutics is not currently profitable: it reported a net loss of $114.7M over the trailing twelve months, a -154.9% net margin.
What is Protagonist Therapeutics's earnings per share?
Protagonist Therapeutics's diluted EPS over the trailing twelve months is $-1.82.
Where does Protagonist Therapeutics's income statement data come from?
Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.